Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,…
News
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,…
Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The…
Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The…
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage…
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage…
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023
DURHAM, N.C., Aug. 07, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology…
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023
DURHAM, N.C., Aug. 07, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology…
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused…
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused…
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, Aug….
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, Aug….
MediWound to Report Second Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time YAVNE,…
MediWound to Report Second Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time YAVNE,…
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024 CARMEL, Ind.,…
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024 CARMEL, Ind.,…